Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
2(13%)
Results Posted
44%(4 trials)

Phase Distribution

Ph phase_1
1
7%
Ph phase_4
5
33%
Ph early_phase_1
1
7%
Ph phase_3
2
13%
Ph phase_2
1
7%
Ph not_applicable
5
33%

Phase Distribution

2

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution15 total trials
Early Phase 1First-in-human
1(6.7%)
Phase 1Safety & dosage
1(6.7%)
Phase 2Efficacy & side effects
1(6.7%)
Phase 3Large-scale testing
2(13.3%)
Phase 4Post-market surveillance
5(33.3%)
N/ANon-phased studies
5(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

2

trials recruiting

Total Trials

15

all time

Status Distribution
Active(2)
Completed(9)
Terminated(3)
Other(1)

Detailed Status

Completed9
Withdrawn3
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (6.7%)
Phase 11 (6.7%)
Phase 21 (6.7%)
Phase 32 (13.3%)
Phase 45 (33.3%)
N/A5 (33.3%)

Trials by Status

withdrawn320%
recruiting213%
unknown17%
completed960%

Recent Activity

2 active trials
Showing 5 of 15
recruitingphase_2

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

NCT06046417
recruitingnot_applicable

The Role of Amylin in Bone Metabolism

NCT06186063
completednot_applicable

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

NCT05199714
completedphase_4

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

NCT01841359
withdrawnearly_phase_1

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

NCT04252612
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT06046417Phase 2

A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

Recruiting
NCT06186063Not Applicable

The Role of Amylin in Bone Metabolism

Recruiting
NCT05199714Not Applicable

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

Completed
NCT01841359Phase 4

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

Completed
NCT04252612Early Phase 1

Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

Withdrawn
NCT00505882Phase 4

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Withdrawn
NCT00690235Phase 4

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Completed
NCT01165944Phase 1

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

Withdrawn
NCT01269047Phase 4

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

Completed
NCT00291772Phase 4

Continuous Subcutaneous Infusion of Pramlintide and Insulin

Completed
NCT00206297Phase 3

The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

Completed
NCT00842075Not Applicable

Pramlintide in Adolescents With Type 1 Diabetes

Completed
NCT01137695Phase 3

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

Unknown
NCT00460304Not Applicable

The Effect of Pramlintide on Meal Time Insulin Bolus

Completed
NCT00489645Not Applicable

Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide

Completed

All 15 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
15